Evidence map›Paper›PMID 40960073›Full record

ArticleFuture science OA2025

hPL-conditioned MSC-derived extracellular vesicles exhibit enhanced anticancer effects on MCF7 and A549 cells.

Nidaa A Ababneh, Razan AlDiqs, Sura Nashwan, Mohammad A Ismail, Raghda Barham, Fairouz Nairat, Enas Alwohoush, Shaymaa A Hussein, Tareq Saleh, Abdalla Awidi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nidaa A AbabnehCell Therapy Center, The University of Jordan, Amman, Jordan.
Razan AlDiqsCell Therapy Center, The University of Jordan, Amman, Jordan.
Sura NashwanCell Therapy Center, The University of Jordan, Amman, Jordan.
Mohammad A IsmailCell Therapy Center, The University of Jordan, Amman, Jordan.
Raghda BarhamCell Therapy Center, The University of Jordan, Amman, Jordan.
Fairouz NairatCell Therapy Center, The University of Jordan, Amman, Jordan.
Enas AlwohoushCell Therapy Center, The University of Jordan, Amman, Jordan.
Shaymaa A HusseinCell Therapy Center, The University of Jordan, Amman, Jordan.
Tareq SalehDepartment of Pharmacology & Therapeutics, College of Medicine & Health Sciences, Arabian Gulf University, Manama, Bahrain.
Abdalla AwidiCell Therapy Center, The University of Jordan, Amman, Jordan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMesenchymal stem cells (MSCs) have therapeutic potential due to their differentiation and immune-regulatory capabilities, mainly through the secretion of extracellular vesicles (EVs) which can exhibit pro- and anti-tumor effects.

aimsThis study aimed to investigate the effects of EVs derived from Whorton's jelly derived MSCs (WJMSCs) cultured in fetal bovine serum (FBS) or human platelet lysate (hPL), as xeno-free alternative, on breast (MCF7) and lung (A549) cancer cells.

methodsEVs were isolated from WJMSCs cultured in either FBS or hPL and then applied to cancer cells. Following characterization of EVs, the effects on cancer cell proliferation, apoptosis, senescence, and migration were also assessed.

resultsBoth EV types reduced proliferation in MCF7 and A549 cells at 24 hours, with a sustained effect on MCF7 at 48 hours. Senescence marked by upregulation of the Senescence-associated β-galactosidase (SA-β-gal) was induced in both cell lines, indicating non-apoptotic growth inhibition. WJMSC-hPL-EVs enhanced migration in MCF7 cells despite reduced proliferation, whereas A549 cell migration was time-dependent, as demonstrated by the wound scratch assay.

conclusionWhile the findings show minimal differences between FBS and hPL, the results nonetheless support the potential use of hPL as a viable xeno-free alternative to FBS. Further research is needed to the therapeutic implications.

Indexed as

breast cancercell-free therapyextracellular vesicles (EVs)lung cancerMesenchymal stem cells (MSC)Wharton’s jelly-derived MSCs (WJMSCs)

Identifiers

PMID40960073
PMCPMC12452434

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.